Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 76 Neoplasm Metastasis 12 Neoplasms 10 Neoplasms by Site 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Ovarian Neoplasms 3 Hereditary Sensory and Autonomic Neuropathies 3 Head and Neck Neoplasms 3 Carcinoma, Renal Cell 3 Breast Diseases 3 Recurrence 2 Kidney Neoplasms 2 Endometrial Neoplasms 2 Digestive System Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Advanced Solid Tumors 2 von Hippel-Lindau Disease 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma 1

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × HR+/HER2- Breast Cancer × palbociclib × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡